Using RWE in rare disease drug development: effective innovations with historical controls
European Pharmaceutical Review
SEPTEMBER 22, 2022
Rare disease drug development poses unique challenges that can be overcome by using real-world evidence (RWE). Another benefit is that fewer patients are required in clinical trials using HCs, thereby reducing time to trial completion and speeding drug approval. Patel et al.
Let's personalize your content